Pharmaceutical NanotechnologyNanoencapsulation of psoralidin (cas 18642-23-4) via chitosan and Eudragit S100 for enhancement of oral bioavailability
-
Add time:10/01/2019 Source:sciencedirect.com
psoralidin (cas 18642-23-4) (PL) has recently been attracting more attention as a new anticancer agent candidate. Nevertheless, peroral administration of PL is largely challenged by its insoluble nature and intestinal efflux. This article aimed to develop a nanoencapsulation formulation of PL using water-soluble chitosan and Eudragit S100 and to evaluate its potential for bioavailability enhancement. PL-loaded nanocapsules (PL-NCs) were prepared by a solvent diffusion and high-pressure homogenization technique with Poloxamer 188 as a stabilizer. The resultant PL-NCs were approximately 132.5 nm in particle size and possessed a high entrapment efficiency (98.1%). In vitro release showed that PL was released less from the nanocapsules due to electrostatic complexation. A lipolytic experiment demonstrated that our prepared PL-NCs were not degraded by lipase, in contrast with the most commonly used lipid nanoparticles. Furthermore, PL-NCs appeared to have less affinity for intestinal mucins. Following oral administration, the bioavailability of PL was significantly enhanced via the PL-NCs, with a value of 339.02% relative to the reference (suspensions). Excellent intestinal adhesion and transepithelial permeability accounted for the enhancement of oral bioavailability. Taken together, these results indicate that nanoencapsulation of PL with chitosan and Eudragit S100 is a promising strategy for improved PL oral delivery.
We also recommend Trading Suppliers and Manufacturers of psoralidin (cas 18642-23-4). Pls Click Website Link as below: cas 18642-23-4 suppliers
Prev:Synthesis of psoralidin (cas 18642-23-4) derivatives and their anticancer activity: first synthesis of Lespeflorin I1
Next:psoralidin (cas 18642-23-4), a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- psoralidin (cas 18642-23-4), a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia09/28/2019
- Synthesis of psoralidin (cas 18642-23-4) derivatives and their anticancer activity: first synthesis of Lespeflorin I109/27/2019
- Comparison of the in vitro metabolism of psoralidin (cas 18642-23-4) among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes09/26/2019
- RESEARCH ARTICLE: Pharmacokinetics, Pharmacodynamics and Drug Transport and MetabolismRegio- and Isoform-Specific Glucuronidation of psoralidin (cas 18642-23-4): Evaluation of 3-O-Glucuronidation as a Functional Marker for UGT1A909/25/2019
- Molecular and cellular pharmacologypsoralidin (cas 18642-23-4), a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts09/24/2019
- psoralidin (cas 18642-23-4) suppresses osteoclastogenesis in BMMs and attenuates LPS-mediated osteolysis by inhibiting inflammatory cytokines09/10/2019
- The higher osteoprotective activity of psoralidin (cas 18642-23-4) in vivo than coumestrol is attributed by its presence of an isopentenyl group and through activated PI3K/Akt axis09/09/2019
- Original ArticleEffect and mechanism of psoralidin (cas 18642-23-4) on promoting osteogenesis and inhibiting adipogenesis09/08/2019
- ReviewMechanisms explaining the efficacy of psoralidin (cas 18642-23-4) in cancer and osteoporosis, a review09/07/2019
